Inactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic Mouse
Open Access
- 19 August 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0136420
Abstract
Epidemics and outbreaks caused by infections of several subgenotypes of EV71 and other serotypes of coxsackie A viruses have raised serious public health concerns in the Asia-Pacific region. These concerns highlight the urgent need to develop a scalable manufacturing platform for producing an effective and sufficient quantity of vaccines against deadly enteroviruses. In this report, we present a platform for the large-scale production of a vaccine based on the inactivated EV71(E59-B4) virus. The viruses were produced in Vero cells in a 200 L bioreactor with serum-free medium, and the viral titer reached 107 TCID50/mL 10 days after infection when using an MOI of 10−4. The EV71 virus particles were harvested and purified by sucrose density gradient centrifugation. Fractions containing viral particles were pooled based on ELISA and SDS-PAGE. TEM was used to characterize the morphologies of the viral particles. To evaluate the cross-protective efficacy of the EV71 vaccine, the pooled antigens were combined with squalene-based adjuvant (AddaVAX) or aluminum phosphate (AlPO4) and tested in human SCARB2 transgenic (Tg) mice. The Tg mice immunized with either the AddaVAX- or AlPO4-adjuvanted EV71 vaccine were fully protected from challenges by the subgenotype C2 and C4 viruses, and surviving animals did not show any degree of neurological paralysis symptoms or muscle damage. Vaccine treatments significantly reduced virus antigen presented in the central nervous system of Tg mice and alleviated the virus-associated inflammatory response. These results strongly suggest that this preparation results in an efficacious vaccine and that the microcarrier/bioreactor platform offers a superior alternative to the previously described roller-bottle system.Keywords
This publication has 45 references indexed in Scilit:
- Development of enterovirus 71 vaccinesExpert Review of Vaccines, 2010
- High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell cultureVaccine, 2007
- New low-viscosity overlay medium for viral plaque assaysVirology Journal, 2006
- Genetic Characteristics of Human Enterovirus 71 and Coxsackievirus A16 Circulating from 1999 to 2004 in Shenzhen, People's Republic of ChinaJournal of Clinical Microbiology, 2005
- Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine developmentVaccine, 2004
- A Mouse-Adapted Enterovirus 71 Strain Causes Neurological Disease in Mice after Oral InfectionJournal of Virology, 2004
- Proinflammatory Cytokine Reactions in Enterovirus 71 Infections of the Central Nervous SystemClinical Infectious Diseases, 2003
- Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virusVaccine, 2001
- Neurologic Complications in Children with Enterovirus 71 InfectionNew England Journal of Medicine, 1999
- An Epidemic of Enterovirus 71 Infection in TaiwanNew England Journal of Medicine, 1999